EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR

Weiya Li, Yuheng Jia, Hongde Li, Yusuke Kobari, Junli Li, Yuan Feng, Yong Peng, Jiafu Wei, Zhengang Zhao, Tianyuan Xiong, Haoran Yang, Chengxiang Song und 8 weitere

JACC: Cardiovascular Interventions · 2025

DOI: 10.1016/j.jcin.2025.05.045 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Weiya Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiov…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve, Bicuspid Aortic Valve Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Differences in long-term clinical outcomes following transcatheter aortic valve replacement (TAVR) in different anatomical subtypes of aortic valve stenosis (AS), specifically tricuspid aortic valves (TAV) and bicuspid aortic valves (BAV) of types 0 (BAV-0) and 1 (BAV-1), are not well understood. OBJECTIVES: The authors sought to report and compare the long-term clinical outcomes among patients with different anatomical subtypes of AS undergoing TAVR. METHODS: We conducted an international retrospective cohort study involving patients who underwent TAVR for severe AS at 3 large, high-volume heart centers in China, Germany, and Denmark before October 2018. Five-year follow-up ended on October 30, 2023, and the primary endpoint was all-cause mortality. RESULTS: A total of 2,553 AS patients (BAV-0: n = 134; BAV-1: n = 305; TAV: n = 2,114) who underwent TAVR more than 5 years ago were included. The mean age of this cohort was 79.9 ± 6.8 years, and the median Society of Thoracic Surgeons score was 3.6% [Q1-Q3: 2.4%-5.4%]. The median follow-up time was 3.24 years (Q1-Q3: 1.25-5.00 years). At 5 years, BAV-1 (adjusted HR: 2.38 [95% CI: 1.32-4.28]; P = 0.004) and TAV (adjusted HR: 3.02 [95% CI: 1.71-5.31]; P < 0.001) had a higher risk for all-cause mortality after TAVR compared with BAV-0. BAV patients who were treated with balloon-expandable valves had a higher long-term all-cause mortality (41.7% [28.5%-52.5%] vs 23.6% [17.9%-28.8%]; HR: 1.63 [95% CI: 1.05-2.51]; P = 0.028) compared with those with self-expanding valves. CONCLUSIONS: Among patients with severe AS undergoing TAVR, BAV-0 was associated with a better long-term prognosis compared with TAV and BAV-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisAortic ValveBicuspid Aortic Valve DiseaseHumansMaleFemaleRetrospective StudiesTreatment OutcomeTime FactorsAgedAged, 80 and overRisk FactorsRisk AssessmentGermanySeverity of Illness IndexDenmarkChina

Stichwörter der Autor:innen

all-cause mortalityaortic valve stenosisbicuspid aortic valvetranscatheter tricuspid valve replacement

Autor:innen und Institutionen

  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, Ch…
  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China; Cardiac Structure and Function Research Key Laboratory of Sichuan Province, We…
  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Förderung

  • National Natural Science Foundation of China
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Li, W., Jia, Y., Li, H., Kobari, Y., Li, J., Feng, Y., Peng, Y., Wei, J., Zhao, Z., Xiong, T., Yang, H., Song, C., Lei, W., Peng, S., Yin, Y., Qiao, X., Wang, D., Kim, W. K., De Backer, O., & Chen, M. (2025). Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.05.045

Vancouver

Li W, Jia Y, Li H, Kobari Y, Li J, Feng Y, et al. Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.05.045

BibTeX
@article{Li2025,
  author = {Li, Weiya and Jia, Yuheng and Li, Hongde and Kobari, Yusuke and Li, Junli and Feng, Yuan and Peng, Yong and Wei, Jiafu and Zhao, Zhengang and Xiong, Tianyuan and Yang, Haoran and Song, Chengxiang and Lei, Wenhua and Peng, Shiqin and Yin, Yue and Qiao, Xuechen and Wang, Duolao and Kim, Won-Keun and De Backer, Ole and Chen, Mao},
  title = {Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1016/j.jcin.2025.05.045}
}
Kostenlos starten →